|
Consolidated Financial Statement Detail (Details)
|
12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Dec. 31, 2013
Five year warrants issued in March 2012 [Member]
USD ($)
|
Dec. 31, 2013
Five year warrants issued in March 2012 [Member]
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
|
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
|
Dec. 31, 2013
Warrants issued to private investors [Member]
USD ($)
|
Dec. 31, 2012
Warrants issued to private investors [Member]
USD ($)
|
Jun. 30, 2009
Warrants issued to private investors [Member]
|
Dec. 31, 2013
Equipment and Furniture [Member]
USD ($)
|
Dec. 31, 2012
Equipment and Furniture [Member]
USD ($)
|
Dec. 31, 2013
Buildings, Leasehold and Building Improvements [Member]
USD ($)
|
Dec. 31, 2012
Buildings, Leasehold and Building Improvements [Member]
USD ($)
|
Dec. 31, 2013
Construction-in-Progress [Member]
USD ($)
|
Dec. 31, 2012
Construction-in-Progress [Member]
USD ($)
|
Dec. 31, 2013
Land [Member]
USD ($)
|
Dec. 31, 2012
Land [Member]
USD ($)
|
Dec. 31, 2013
Options Contract [Member]
USD ($)
Contract
|
Dec. 31, 2012
Options Contract [Member]
USD ($)
|
Dec. 31, 2011
Options Contract [Member]
USD ($)
|
Dec. 31, 2013
Options Contract [Member]
EUR (€)
|
Dec. 31, 2013
Option Contract 1 [Member]
EUR (€)
|
Dec. 31, 2013
Option Contract 2 [Member]
EUR (€)
|
Dec. 31, 2013
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2012
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2013
Money Market Funds [Member]
USD ($)
|
Dec. 31, 2012
Money Market Funds [Member]
USD ($)
|
|
| Cash and Cash Equivalents [Line Items] | |||||||||||||||||||||||||||||||
| Cash equivalents | $ 18,900,000 | $ 7,800,000 | $ 82,800,000 | $ 37,500,000 | |||||||||||||||||||||||||||
| Short-term Investments [Abstract] | |||||||||||||||||||||||||||||||
| Short-term investments | 19,990,000 | 39,987,000 | |||||||||||||||||||||||||||||
| Derivative [Line Items] | |||||||||||||||||||||||||||||||
| Notional amount of derivative liability | 15,000,000 | ||||||||||||||||||||||||||||||
| Number of foreign exchange option contracts | 2 | ||||||||||||||||||||||||||||||
| Derivative, amount of hedged item | 1,500,000 | 15,000,000 | |||||||||||||||||||||||||||||
| Derivative, premiums | 1,500,000 | ||||||||||||||||||||||||||||||
| Derivative fair value | 400,000 | 500,000 | |||||||||||||||||||||||||||||
| Derivative, loss | 100,000 | 700,000 | 300,000 | ||||||||||||||||||||||||||||
| Receivables [Abstract] | |||||||||||||||||||||||||||||||
| Trade receivables, net | 3,731,000 | 7,477,000 | |||||||||||||||||||||||||||||
| Other receivables | 50,000 | 772,000 | |||||||||||||||||||||||||||||
| Total | 3,781,000 | 8,249,000 | |||||||||||||||||||||||||||||
| Property, Plant and Equipment [Line Items] | |||||||||||||||||||||||||||||||
| Property and equipment, gross | 38,216,000 | 49,532,000 | 28,365,000 | 25,734,000 | 9,316,000 | 21,656,000 | 225,000 | 1,832,000 | 310,000 | 310,000 | |||||||||||||||||||||
| Less: Accumulated depreciation and amortization | (31,760,000) | (41,389,000) | |||||||||||||||||||||||||||||
| Property and equipment, net | 6,456,000 | 8,143,000 | |||||||||||||||||||||||||||||
| Depreciation and amortization expense | 2,575,000 | 4,124,000 | 5,357,000 | ||||||||||||||||||||||||||||
| Accrued Liabilities [Abstract] | |||||||||||||||||||||||||||||||
| Accrued management incentive compensation | 4,386,000 | 3,978,000 | |||||||||||||||||||||||||||||
| Accrued payroll and other benefits | 3,009,000 | 2,461,000 | |||||||||||||||||||||||||||||
| Accrued clinical trial costs | 878,000 | 4,702,000 | |||||||||||||||||||||||||||||
| Other | 1,661,000 | 1,904,000 | |||||||||||||||||||||||||||||
| Total | 9,934,000 | 13,045,000 | |||||||||||||||||||||||||||||
| Deferred Revenue [Abstract] | |||||||||||||||||||||||||||||||
| Revenue deferred | 1,500,000 | 5,900,000 | |||||||||||||||||||||||||||||
| Revenue recognized | 4,900,000 | 9,400,000 | |||||||||||||||||||||||||||||
| Class of Warrant or Right [Line Items] | |||||||||||||||||||||||||||||||
| Warrants outstanding (in shares) | 1,260,000 | 12,562,682 | 14,834,577 | 347,826 | |||||||||||||||||||||||||||
| Exercise price of warrants (in dollars per share) | $ 10.50 | $ 1.76 | $ 19.50 | ||||||||||||||||||||||||||||
| Fair value of warrant liability | 15,000,000 | 68,700,000 | 1,200,000 | 100,000 | |||||||||||||||||||||||||||
| Gain (loss) on revaluation of warrant liability | 59,900,000 | (1,100,000) | |||||||||||||||||||||||||||||
| Warrant Term | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||
| Reclassification of warrant liability to equity | $ 6,200,000 | ||||||||||||||||||||||||||||||